Home › Trials › NCT06505018

Using a telemonitoring platform to support treatment for metastatic triple-negative breast cancer

A Randomized Phase III Study Comparing the Digital Telemonitoring Platform "CUREETY TECHCARE" to Usual Standard of Care in Patients With Triple Negative Metastatic Breast Cancer Initiating a First-line Systemic Treatment

NA · UNICANCER · NCT06505018

This study is testing if a new telemonitoring system can help people with metastatic triple-negative breast cancer feel better and stay out of the hospital while they start their first treatment.

Quick facts

PhaseNA
Study typeInterventional
Enrollment472 (estimated)
Ages18 Years and up
SexAll
SponsorUNICANCER (other)
Locations51 sites (Arras and 50 other locations)
Trial IDNCT06505018 on ClinicalTrials.gov

What this trial studies

This clinical trial evaluates the effectiveness of the telemonitoring platform 'CUREETY TECHCARE' in conjunction with standard care for patients with metastatic triple-negative breast cancer who are starting their first-line treatment. The study aims to determine if telemonitoring can improve patient quality of life, reduce hospitalization rates, and enhance overall survival compared to standard care alone. Participants will report their symptoms through the platform, which will analyze their condition and provide feedback to both patients and medical staff. The trial compares outcomes between those using the telemonitoring platform and those receiving only standard care.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with histologically confirmed metastatic triple-negative breast cancer who are starting first-line systemic treatment.

Not a fit: Patients who are not initiating treatment or have a life expectancy of less than six months may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could lead to improved quality of life and better health outcomes for patients with metastatic triple-negative breast cancer.

How similar studies have performed: Other studies have shown promising results with telemonitoring in cancer care, suggesting potential benefits in patient management and outcomes.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Signed a written informed consent form prior to participate in the study. Note: In case of physical incapacitation, a trusted representative of their choice, which is not the Investigator or sponsor, can sign on the behalf of the patients
* Patients ≥18 years of age.
* Patient with histologically documented metastatic triple negative breast cancer (ER (Oestrogen receptor) and PR (Progesterone receptor) \<10%, Her2 negative status).
* Life expectancy \> 6 months as per investigator estimate.
* Patient initiating a marketed authorized first-line systemic treatment in the metastatic setting.
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2.
* Patient having completed the EORTC QLQ-C30 and EORTC QLQ-BR45 at baseline (response to questions 29 and 30 of EORTC QLQ-C30 at baseline are mandatory)
* Affiliated to the social security system or equivalent health insurance.
* Patient able and willing to complete web-based self-reported questionnaires, from initiation of first-line treatment and for the duration of the study (over multiple treatment lines)
* Patient has access to a computer, tablet, or smartphone connected to the Internet.

Exclusion Criteria:

* Participation in another clinical trial using telemonitoring.
* Physical or psychological incapacity of the patient to use the digital telemonitoring Cureety Techcare, according to the investigator's discretion.
* Patient deprived of their liberty or under protective custody or guardianship.

Where this trial is running

Arras and 50 other locations

+1 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Metastatic Triple-Negative Breast Carcinoma, Telemonitoring, Triple Negative Breast Cancer, Cureety, Adverse events

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.